Rigel Pharmaceuticals published final Phase 1/2 ARROW study data in the Journal of Clinical Oncology for pralsetinib (Gavreto) in metastatic RET fusion-positive NSCLC, adding 42 months of follow-up to earlier reports. In patients with measurable disease (n=259), the study reported an overall response rate of 70%, including 7% complete responses and 63% partial responses, alongside a manageable safety profile. The company said three treatment-related deaths occurred in treatment-naive patients in Asia, with no new safety signals and no hypersensitivity reactions in patients previously treated with immunotherapies. Investigators highlighted responses among patients with baseline measurable CNS metastases, reinforcing pralsetinib’s potential in everyday treatment settings where brain involvement is common.